Welcome to our dedicated page for Eledon Pharmaceuticals SEC filings (Ticker: ELDN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Eledon Pharmaceuticals, Inc. (ELDN) SEC filings page provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Eledon is a clinical stage biotechnology company focused on immune-modulating therapies built around the CD40 Ligand (CD40L) pathway, with its common stock listed on the Nasdaq Capital Market under the symbol ELDN, as noted in its Form 8-K filings.
Through this page, readers can review key documents such as annual reports on Form 10-K and quarterly reports on Form 10-Q, which describe Eledon’s clinical programs for its lead investigational product tegoprubart, risk factors, and financial position. Current reports on Form 8-K provide more targeted updates, including material events related to clinical data disclosures, financing transactions and other significant corporate developments.
For example, an 8-K dated November 12, 2025 outlines an underwriting agreement for an underwritten public offering of common stock and pre-funded warrants, including the intended use of net proceeds to support continued clinical development and pipeline advancement. Other 8-K filings describe preliminary cash, cash equivalents and short-term investment balances, as well as press releases announcing Phase 2 BESTOW trial results and updated data from a Phase 1b kidney transplant study.
On Stock Titan, these filings are supplemented by AI-powered summaries that explain the main points of lengthy documents, helping users quickly understand topics such as capital raises, clinical trial disclosures and selected financial information. Real-time updates from EDGAR allow timely viewing of new ELDN filings, while access to forms like 10-K, 10-Q and 8-K supports deeper analysis of Eledon’s clinical-stage operations, financing activities and risk disclosures.
Eledon Pharmaceuticals director Keith Katkin reported the vesting and settlement of restricted stock units into common shares. On January 10, 2026, 8,575 restricted stock units converted into 8,575 shares of Eledon Pharmaceuticals common stock at a price of $0 per share, reflected as a transaction coded "M". These RSUs were originally granted on January 10, 2025 and vested 100% on January 10, 2026. Following the transaction, Katkin beneficially owned 8,575 shares of common stock directly.
Eledon Pharmaceuticals director June Lee reported the vesting and settlement of restricted stock units into common shares. On January 10, 2026, 3,430 restricted stock units converted into 3,430 shares of common stock at a price of $0 per share, leaving Lee with 3,430 common shares held directly after the transaction.
The footnote explains that these shares came from restricted stock units granted on January 10, 2025, which vested 100% on January 10, 2026 on a one-for-one basis into common stock. Following the conversion, the derivative position in these restricted stock units was reduced to zero.
Eledon Pharmaceuticals director reports RSU vesting and share settlement. Director James A. Robinson Jr. settled 3,430 restricted stock units (RSUs) into 3,430 shares of common stock on January 10, 2026, in a transaction coded "M" at a price of $0 per share. The RSUs were originally granted on January 10, 2025 and vested 100% on January 10, 2026.
Following this settlement, Robinson directly holds 3,430 shares of Eledon Pharmaceuticals common stock. The derivative position in the RSUs reported in this filing is now shown as 0 derivative securities beneficially owned, reflecting the full conversion into common shares.
Eledon Pharmaceuticals reports a Q3 2025 net loss of $17.5 million, driven by $19.1 million of operating expenses, mainly research and development on its lead anti-CD40L antibody tegoprubart. For the first nine months of 2025, the net loss was $35.2 million on $61.8 million of operating expenses, reflecting heavier R&D investment versus 2024.
At September 30, 2025, Eledon held $3.7 million in cash and cash equivalents and $89.7 million in short-term investments, for total liquid resources of $93.4 million and working capital of $82.0 million. Management believes this is sufficient to fund planned operations for at least 12 months from the filing date, while noting that additional financing will be needed to support longer-term plans.
Warrant liabilities declined to $21.9 million from $44.9 million at year-end 2024, producing a $22.9 million non-cash gain over nine months. The company also restated prior financial statements to treat its Series X and X1 non-voting convertible preferred stock as a separate class for earnings per share and to classify it as temporary equity due to certain contingent redemption features.
Eledon Pharmaceuticals announced an underwritten public offering of 15,152,485 shares of common stock at $1.65 per share and pre-funded warrants priced at $1.649 each, exercisable for up to 15,151,515 shares at an exercise price of $0.001 per share.
The underwriters have a 30‑day option to purchase up to 4,545,600 additional shares. Estimated net proceeds to the company are approximately $46.5 million, or $53.6 million if the option is exercised in full. Closing is expected on November 13, 2025, subject to customary conditions. Eledon plans to use proceeds to support continued clinical development, advance pipeline programs, and for general corporate purposes.
Certain officers and directors agreed to 60‑day lock‑ups from November 12, 2025. Pre‑funded warrants include a beneficial ownership cap of 4.99% (or 9.99% at holder election), adjustable with 61 days’ notice, not to exceed 19.99% to comply with Nasdaq rules.
Eledon Pharmaceuticals (ELDN) launched a primary offering of 15,152,485 shares and pre‑funded warrants to purchase up to 15,151,515 shares. The public offering price is $1.65 per share and $1.649 per pre‑funded warrant, with warrant exercise price of $0.001 per share. Gross proceeds are $49,986,448, less $3,000,096 in underwriting discounts, for proceeds to the company of $46,986,352 before expenses. The underwriters have a 30‑day option to buy up to 4,545,600 additional shares.
The company estimates net proceeds of approximately $46.5 million (or about $53.6 million if the option is fully exercised), to fund continued clinical development and general corporate purposes. Pre‑funded warrants are not listed and include a 4.99% (or 9.99% at holder’s election) beneficial ownership cap. Shares outstanding were 59,881,775 as of June 30, 2025; this is a baseline figure, not the amount being offered.
Eledon Pharmaceuticals (ELDN) filed a preliminary prospectus supplement for a primary offering of common stock and, in lieu of shares to certain investors, pre-funded warrants. Each pre-funded warrant will be priced at the share offering price minus $0.001 and carries a $0.001 per‑share exercise price. Leerink Partners and Cantor are joint bookrunning managers, and the underwriters have a 30‑day option to purchase additional shares. The pre-funded warrants will not be listed. ELDN’s common stock trades on Nasdaq; the last reported price was $2.25.
The company highlighted topline Phase 2 BESTOW data in kidney transplantation: tegoprubart showed 12‑month eGFR of ~69 mL/min/1.73 m² (n=51) versus 66 for tacrolimus (n=56). The primary endpoint did not reach statistical significance, while a composite efficacy‑failure endpoint was 22% for tegoprubart versus 17% for tacrolimus, which the company states demonstrated non‑inferiority using a 20% margin. Safety signals favored tegoprubart on several measures, including new‑onset diabetes and tremor.
Preliminary, unaudited cash, cash equivalents and short‑term investments were approximately $93.4 million as of September 30, 2025. Net proceeds are intended to support clinical development and general corporate purposes.
Eledon Pharmaceuticals furnished an 8-K announcing an estimated $93.4 million in cash, cash equivalents, and short-term investments as of September 30, 2025. The company described this figure as unaudited, preliminary, and subject to completion of financial closing procedures and management review.
Eledon also disclosed it issued a press release with results from its Phase 2 BESTOW trial evaluating tegoprubart in de novo kidney transplant patients, and plans a conference call on November 7, 2025 to discuss updated data. The 8-K states the Item 2.02 and Item 7.01 information, including the press release, is being furnished and not filed under the Exchange Act.
Eledon Pharmaceuticals (ELDN) reported continued clinical-stage activity focused on tegoprubart, with increased clinical and manufacturing spending to support Phase 1b, Phase 2 BESTOW and a Phase 2 open-label extension. The company disclosed material risk factors including a short operating history, sustained operating losses, the need for additional financing, and potential dilution from multiple warrant and equity programs. Share structure updates and equity programs are described, including a $75.0 million ATM shelf (not yet used), recent registered and private offerings with pre-funded warrants, and designated preferred share series. The report emphasizes reliance on CROs and CMOs, regulatory and enrollment risks, and increased personnel and professional costs tied to expanded development activity.
Eledon Pharmaceuticals (ELDN) reports continued clinical-stage operations focused on tegoprubart and related development programs. The company operates as a single reporting segment with the chief executive officer as the CODM. It has incurred significant operating losses and states it will require additional funding to complete development of its lead candidate. Recent activity increased expenses: a $4.0 million rise tied to kidney transplantation programs, $0.9 million higher manufacturing costs, $0.7 million higher personnel costs and $0.7 million higher stock-based compensation. The company established an "at-the-market" equity program for up to $75.0 million (Shelf effective October 2, 2024) but has not sold shares under it as of March 31, 2025. Capital structure disclosures include 59,881,775 common shares outstanding at March 31, 2025 and several series of non-voting convertible preferred stock and pre-funded warrants outstanding.